A Therapy for a Rare Neurodegenerative Disease Moves Towards Regulatory Review

Marc Martinell, co-founder and CEO of Minoryx, discusses X-ALD, the company’s experimental therapy leriglitizone, and why it’s being viewed as a potential treatment for other rare CNS diseases.